Skip to main content
Clinical Trials/NCT02654249
NCT02654249
Completed
N/A

Prospective Multicenter Randomized Trial About Transanal Hemorrhoidal Dearterialization With Mucopexy (THD) Versus Ligasure Hemorrhoidectomy for Grade III and IV Hemorrhoids

Hospital Universitari de Bellvitge10 sites in 1 country80 target enrollmentDecember 2015
ConditionsHemorrhoids

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hemorrhoids
Sponsor
Hospital Universitari de Bellvitge
Enrollment
80
Locations
10
Primary Endpoint
Post-operative pain
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The study evaluates postoperative pain, morbidity, recurrence and quality of life, comparing two different strategies in the treatment of grade III and IV hemorrhoids: transanal hemorrhoidal dearterialization with mucopexy (THD) versus hemorrhoidectomy by Ligasure™.

Detailed Description

Transanal hemorrhoidal dearterialization (THD)‪ uses a specially developed anoscope combined with a Doppler transducer to identify the hemorrhoidal arteries. A suture ligation is performed to effectively decrease the blood flow to the hemorrhoidal plexus. In case of redundant prolapse, the prolapsed mucosa is lifted (mucopexy). THD procedure is performed without any incisions or removal of the hemorrhoidal tissue and moreover the suture line is above the dentate line, so post-operative pain and morbidities seem to be minimized in these patients. This technique differs from Ligasure hemorrhoidectomy, which focuses on excising the hemorrhoidal tissue. This prospective, randomized, multicenter and controlled trial compares post-operative pain, morbidities, quality of life, fecal incontinence and recurrence rate in patients treated for grade III and IV hemorrhoids with THD with mucopexy versus Ligasure hemorrhoidectomy.

Registry
clinicaltrials.gov
Start Date
December 2015
End Date
January 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Hospital Universitari de Bellvitge
Responsible Party
Principal Investigator
Principal Investigator

Sebastiano Biondo

MD, PhD

Hospital Universitari de Bellvitge

Eligibility Criteria

Inclusion Criteria

  • Patients with grade III and IV hemorrhoids according to Goligher classification
  • Patients ASA I, II or III and adequate hematological, renal and hepatic function
  • Patients who signed informed consent

Exclusion Criteria

  • Altered cognitive state that prevents collaboration in the study or patients who can neither read nor write
  • Fecal incontinence
  • Anal sphincter lesions
  • Recurrent hemorrhoids after previous surgical tratment
  • Previous anorectal surgery except banding, botulinum toxin injection and thrombectomy for hemorrhoid thrombosis
  • Injection sclerotherapy during the last five years
  • Concomitant anorectal disease (anal fistula, anal fissure, anal stenosis, rectocele, enterocele, anal condilomatosis).
  • Concomitant diagnosis of functional pelvic floor disease, inflammatory bowel disease and previous pelvic radiotherapy
  • Concomitant diagnosis of colorectal neoplasia or other neoplasia
  • Patients ASA IV, V

Outcomes

Primary Outcomes

Post-operative pain

Time Frame: within the first 30 days after surgery

Post-operative pain by simple verbal numerical scale (0-10), the Andersen scale (0-5) and the taken pain medicacions will be recorded by the patients on a specific book during the first thirty days after surgery.

Secondary Outcomes

  • Quality of life(At 1 month and at 1 and 2 years after surgery)
  • Specific disabilities (fecal incontinence and costipation)(At the day 15, 30 and at 1 and 2 years after surgery)
  • Post-operative morbidity(within the first 30 days after surgery)
  • Hemorrhoid recurrence(At 1 and 2 years after surgery)
  • Satisfaction after surgery(At the day 15, 30 and at 1 and 2 years after surgery)

Study Sites (10)

Loading locations...

Similar Trials